EGFR and non-small cell lung carcinoma: The efficacy of second-generation EGFR-TKI afatinib combined with bevacizumab as first-line therapy for patients with advanced EGFR-mutated NSCLC has been recently investigated in a clinical trial, but the results are not clear [18].